Quick Takeaways
- Briggs Morrison has 6 issuer positions tracked on this page.
- Estimated disclosed ownership value: $2,264,226.
- Recent insider filing activity is available below.
- Info
- Insider Ownership
Insider Trading & Ownership of Briggs Morrison
- Location
- Waltham, MA
- Summary
- The estimated net worth of Briggs Morrison is at least $2,264,226 dollars as of 09 Mar 2026. Briggs Morrison is the Director of ARVINAS, INC. and owns shares of ARVINAS, INC. (ARVN) stock worth about $1.43M. Briggs Morrison is the Director of Syndax Pharmaceuticals Inc and owns shares of Syndax Pharmaceuticals Inc (SNDX) stock worth about $636.3K. Briggs Morrison is the Director of CRISPR Therapeutics AG and owns shares of CRISPR Therapeutics AG (CRSP) stock worth about $195.8K.
- Signature
- /s/ Jared Freedberg, as attorney-in-fact for Briggs Morrison
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Briggs Morrison and return when a new Insider Trading filing appears.
This tracks SEC filing changes for this page using existing product update flows.
What Changed
- Largest disclosed position: ARVINAS, INC. ($1,432,137).
- Past-year value change for that position: +$495,080.
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Official SEC Source
Filed on Form 4
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
See Original FilingOwnership of Briggs Morrison
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| ARVN | ARVINAS, INC. | Director | $1,432,137 | +$495,080 | +53% | 06 Mar 2026 |
| SNDX | Syndax Pharmaceuticals Inc | Director | $636,283 | 07 Feb 2024 | ||
| CRSP | CRISPR Therapeutics AG | Director | $195,806 | 05 Jun 2025 | ||
| CARM | Carisma Therapeutics Inc. | Director | 26 Jun 2024 | |||
| RPTX | Repare Therapeutics Inc. | Director | 17 Jun 2024 | |||
| HOWL | Werewolf Therapeutics, Inc. | Director | 12 Jun 2025 |
Insider Transactions Reported by Briggs Morrison:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.